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Table 1. Comparison of patient demographics and characteristics of intravitreal bevacizumab and triamcinolone acetonide
injection group
Bevacizumab 
injection group
Triamcinolone acetonide 
injection group
p-value between 
injection groups
Age (mean±SD, range)           56.86±9.64 (37-73)             59.42±11.56 (33-78) 0.407
*
Sex (%)
   Male
   Female
  10 (45.5)
  12 (54.5)
11 (39.3)
17 (60.7)
0.621
†
Pre injection BCVA (logMAR, mean±SD) 0.60±0.41 0.67±0.28 0.160
*
Pre injection CMT (μm, mean±SD) 399.64±128.32 466.39±121.29 0.057
*
Pre injection IOP (mmHg, mean±SD) 13.09±2.07 13.36±2.57 0.694
*
Mean time between injection and 
diagnosis (wk, range)   13.6 (0-22)   14.4 (8-28)
Associated systemic disease (%)
   Hypertension
   Diabetes mellitus
   Hyperlipidemia
     14 (63.6)
       5 (22.7)
     2 (9.0)
     16 (57.1)
       7 (25.0)
       3 (10.7)
BCVA=best corrected visual acuity; logMAR=logarithm of the minimal angle of resolution; CMT=center macular thickness; IOP=intraocular pressure.
*Independent t-test; 
†Chi-square test.
Bevacizumab and Triamcinolone for Branch 
Vein Occlusion
To the Editor
Dear Editor,
I write to you with regard to the article by Kim and Park, 
titled ‘Comparison between intravitreal bevacizumab and tri-
amcinolone for macular edema secondary to branch retinal 
vein occlusion’ [1]. Their study compared the effects of stand-
ard doses of bevacizumab (1.25 mg) and triamcinolone (4 
mg) intravitreally for the treatment of macular edema (ME) 
secondary to branch retinal vein occlusion (BRVO). The re-
sults in terms of improvements in visual acuity and central 
macular thickness were similar between those treated with 
intravitreal bevacizumab (IVB) and those treated with intra-
vitreal triamcinolone (IVT). Despite the seemingly promis-
ing results, there are two concerns we would like to address.
First, subjects were given treatment without being given 
an observation period to allow for spontaneous resolution. 
The natural history of BRVO can be variable and can resolve 
without treatment, especially for cases in which perfusion is 
re-established after the initial attack. In the classic Branch 
Vein Occlusion Study (BVOS) [2], subjects were observed 
for spontaneous resolution for at least 12 weeks, and, in the 
cases in which resolution was unlikely, treatment was 
offered. In the current study, both IVB and IVT were given 
without an observation period in whichspontaneous reso-
lution may occur. Although the mean time from diagnosis to 
injection was more than 12 weeks in both groups, some pa-
tients received injection treatment as early as 0 weeks after 
diagnosis of BRVO (Table 1) [1]. This may only add poten-
tial risks to eyes in which spontaneous resolution can occur. 
Furthermore, this precluded comparison with the BVOS, 
since the treatment time frames were different. 
Next, the only well-established, evidence-based treatment 
of choice for macular edema secondary to BRVO is grid laser 
treatment, according to the BVOS [2] and the recent Standard 
Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) 
study [3]. In the multi-center randomized trial SCORE study, 
IVT (either 1 mg or 4 mg) failed to produce a superior effect, 
when compared to that of subjects who received grid laser 
treatment, and risk of adverse events was highest in the 4 
mg-IVT treatment arm. Hence, to date, grid laser treatment 
remains the benchmark for other new treatment options in Ian Yat Hin Wong and SP Park. Bevacizumab and Triamcinolone for Branch Vein Occlusion
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comparing effects in eyes with vision loss due to ME from 
BRVO [3]. That being said, if the authors intend to demon-
strate the effectiveness of IVB, comparison with subjects that 
had grid laser treatment, rather than IVT, is required. 
Ian Yat Hin Wong
Department of Ophthalmology, Tung Wah Eastern Hospital, Hong 
Kong
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Reply from the authors
First, the natural course of branch retinal vein occlusion 
(BRVO) with macular edema (ME) is now known to be very 
diverse, resolving without treatment in many cases [1]. Thus, 
I think that it is right to control the initial treatment period, In 
this regard, I agree with the comment of Wong I. However, in 
our study, the mean times and ranges between diagnosis and 
injection were 14.4 weeks (8 to 28 weeks) in the intravitreal 
triamcinolone (IVT) group and 13.6 weeks (0 to 22 weeks) in 
the IVB group. According to the distribution, in most cases, 
the time frames were more than eight weeks, with only a 
small number of patients in each group having 0 to 4 weeks 
between diagnosis and treatment. The distribution tended to 
be slightly negatively skewed. In addition, there were no 
differences in the results, even if we excluded these cases 
with the time frames of 0 to 4 weeks. In conclusion, even if 
we controlledthe interval between diagnosis and initial 
treatment, the results suggest that there is no significant 
difference. However, additional research, including more 
control subjects, may be warranted.
Secondly, the recent results of the Standard Care vs 
Corticosteroid for Retinal Vein Occlusion study have shown 
that, just as we suspected, grid laser treatment is effective and 
safe treatment [2]. Based on these results, grid laser treat-
ment became the mainstay in the treatment of BRVO with 
ME [2] and is expected to play an important role in the treat-
ment of other disease entities. Unfortunately, just as Wong I 
commented, we do not compare our treatment with efficacy 
and safety of grid laser treatment. However, when with intra-
vitreal bevacizumab (IVB) treatment was introduced and 
performing off-label uses in many cases, we intend to study 
the differences in effectiveness and adverse events between 
IVT and IVB from the viewpoint of “injection” [3-5]. Among 
the recent studies, Cheng et al. [5] reported similar results to 
those of our study. Their study is more meaningful with-
respect to the “Asian race”. Consequently, our study shows 
that IVB may be a useful treatment option, as compared with 
IVT, as it results in fewer adverse events. Also, we performed 
a single injection in each group and showed that the single in-
jection-course of BRVO with ME has special significance.
Jin Young Kim, Sung Pyo Park
Department of Ophthalmology, Kangdong Sacred Heart Hospital, 
Hallym University College of Medicine, Seoul, Korea
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